Professor David Goldstein appointed as chief adviser for AstraZeneca’s genomics initiative
pharmafile | September 30, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |
AstraZeneca today announced that Professor David Goldstein will join the Company in the consultative role of Chief Adviser, Genomics to lead its integrated genomics initiative, which was announced in April.
Professor David Goldstein will work in a consultative role to help AstraZeneca’s 10-year initiative to focus on the discovery of new targets and biomarkers linked to molecular mechanism of disease across AstraZeneca’s main therapy areas. Professor Goldstein will continue in his two roles at Columbia University, as Director of the Institute for Genomic Medicine and Professor of Genetics and Development.He has become known for is research on human genetic deiversity, the genetics of disease and pharmacogenetics and will be responsible for the progress of AstraZeneca’s genomics initiative.
Goldstein commented on his appointed by commenting, “AstraZeneca has placed genomics at the centre of its strategy for researching and developing medicines that will change the lives of patients around the world. Having served as the Chair of the company’s genomics advisory panel since 2015, I’m now excited to take on this important role and lead the implementation of the panel’s recommendations. One of my first tasks is to establish a world-leading team to execute AstraZeneca’s ambitious genomics approach across its pipeline.”
Mene Pangalos, Executive Vice President, Innovative Medicines and Early Development and Global Business Development at AstraZeneca, said: “We’re delighted to welcome David to AstraZeneca at a very exciting time for our company and the rapidly evolving field of genomics. Our ambition is to develop life-changing treatments for patients and our genomics strategy is at the heart of this. David is a world-renowned expert in genomics, and his expertise will help to accelerate the integration of genomics across our entire research and development pipeline.”
Professor Goldstein received his PhD in biological sciences from Stanford University in 1994 and has previously held positions at University College London and Duke University, North Carolina. He has published over 250 papers in the field and is a recipient of the Royal Society Wolfson Research Merit Award.
